Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia



Status:Completed
Conditions:Pneumonia
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:September 2015
End Date:May 2017

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia

This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment
of adults with moderate to severe community-acquired bacterial pneumonia.

Lefamulin is a potent, semi-synthetic antibacterial belonging to a novel class known as the
pleuromutilins. Both the intravenous (IV) and oral dosage forms of lefamulin are under
investigation in this study. Lefamulin's in vitro antibacterial profile includes the most
important bacterial pathogens causing respiratory tract infection (RTI). The antibacterial
spectrum comprises S. pneumoniae, H. influenzae, M. catarrhalis, the atypical respiratory
pathogens L. pneumophila, C. pneumoniae, and M. pneumoniae, S. aureus including MRSA and
CA-MRSA, ß-haemolytic streptococci including S. pyogenes and S. agalactiae, and Enterococcus
faecium including vancomycin-resistant enterococci (VRE). Moreover, as demonstrated in
cross-resistance studies, lefamulin remains active against clinical isolates resistant to the
following antimicrobial(s) (classes): macrolides, lincosamides, streptogramin B,
oxazolidinones, tetracyclines, ß lactams, quinolones, trimethoprim-sulfametoxazole,
mupirocin, and vancomycin.

Inclusion Criteria:

1. Be male or female at least 18 years of age.

2. Provide written informed consent and be willing and able to adhere to the
study-specified procedures and restrictions.

3. Have an acute illness (7 days duration) with at least 3 of the following symptoms
consistent with a lower respiratory tract infection (new or worsening):

- Dyspnea

- New or increased cough

- Purulent sputum production

- Chest pain due to pneumonia

4. Have at least 2 of the following vital sign abnormalities:

- Fever (body temperature >38.0°C (100.4°F) measured orally or equivalent
temperature from an alternate body site) or hypothermia (body temperature <35.0°C
(95.0°F) measured orally or equivalent temperature from an alternate body site)

- Hypotension (systolic blood pressure <90 mmHg)

- Tachycardia (heart rate >100 beats/min)

- Tachypnea (respiratory rate >20 breaths/min)

5. Have at least 1 other clinical sign or laboratory finding of CABP:

- Hypoxemia (i.e., O2 saturation <90% on room air or while receiving supplemental
oxygen at subject's baseline requirement or PaO2 <60 mmHg)

- Auscultatory and/or percussion findings consistent with pneumonia (e.g.,
crackles, egophony, dullness)

- White blood cell (WBC) count >10,000 cells/mm3 or <4500 cells/mm3 or >15%
immature neutrophils (bands) regardless of total WBC count

6. Have radiographically-documented pneumonia within 48 hours before enrollment (i.e.,
infiltrates in a lobar or multilobar distribution or diffuse opacities on chest x-ray
or chest computed tomography scan consistent with acute bacterial pneumonia).

7. Have a Pneumonia Outcomes Research Team (PORT) Risk Class ≥III.

Exclusion Criteria:

1. Have received more than a single dose of a short-acting oral or IV antibacterial for
CABP within 72 hours before randomization

2. Require concomitant systemic antibacterial therapy potentially effective against CABP
pathogens

3. Have been hospitalized for 2 or more days within 90 days prior to the onset of
symptoms or have resided in a nursing home or long-term healthcare facility within 30
days prior to the onset of symptoms. NOTE: Residence in an independent living facility
is permitted.

4. Have confirmed or suspected CABP caused by a pathogen known to be resistant to any of
the study drugs (e.g., Pseudomonas aeruginosa, any pathogen of the Enterobacteriaceae
Family) or attributable to etiologies other than community acquired bacterial
pathogens (e.g., ventilator associated pneumonia, hospital acquired bacterial
pneumonia, bacterial aspiration pneumonia, Pneumocystis jiroveci pneumonia or other
fungal pneumonia, viral or mycobacterial infection of the lung).

5. Have a noninfectious cause of pulmonary infiltrates (e.g., pulmonary embolism,
chemical pneumonitis from aspiration, hypersensitivity pneumonia, congestive heart
failure, bronchial obstruction, lung cancer, cystic fibrosis).

6. Have confirmed or suspected pleural empyema (does not include sterile parapneumonic
effusions).

7. Require mechanical ventilation.
We found this trial at
8
sites
Hazard, Kentucky 41701
Phone: 610-816-6648
?
mi
from
Hazard, KY
Click here to add this to my saved trials
Akron, Ohio
Phone: 610-816-6648
?
mi
from
Akron, OH
Click here to add this to my saved trials
Butte, Montana
Phone: 610-816-6648
?
mi
from
Butte, MT
Click here to add this to my saved trials
Dayton, Ohio 45409
Principal Investigator: Hari Polenakovik, MD
Phone: 610-816-6648
?
mi
from
Dayton, OH
Click here to add this to my saved trials
La Plata, Buenos Aires
Phone: 610-816-6648
?
mi
from
La Plata,
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Phone: 610-816-6648
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Shreveport, Louisiana 71103
Phone: 610-816-6648
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Splendora, Texas 77372
Phone: 610-816-6648
?
mi
from
Splendora, TX
Click here to add this to my saved trials